OVERVIEW

Medical Crossfire®: What Informs Our Clinical Decisions in chronic lymphocytic leukemia (CLL) Management? Key Evidence to Stratify Risk and Optimize Sequencing is organized by Physicians' Education Resource, LLC (PER).

Release Date: October 31, 2019
Expiration Date: October 31, 2020

Accreditation:
Physician Credit Designation:
The University of Cincinnati designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
In this online educational program, chaired by William G. Wierda, MD, PhD, top faculty in the field of chronic lymphocytic leukemia (CLL) and including Ian W. Flinn, MD, PhD; Anthony Mato, MD, MSCE; and Paolo Strati, MD, discuss current and emerging evidence-based therapeutics applicable to patients with CLL. The panel members explain risk stratification, therapeutic monitoring, sequencing, and combination strategies for the treatment of CLL in the frontline setting, as well as for relapsed/refractory disease. Discussion also focuses on the role of molecular and cytogenetic testing in CLL at this prolific moment of emerging mechanisms, compounds, and approaches. The faculty offer clinical perspectives and contrasting viewpoints on the application of clinical trial results and distinguish among the new small molecules currently being investigated in CLL. Through a comprehensive discussion of the evolving strategies for management of patients with CLL, participants will encounter practice-changing perspectives with the potential to improve patient outcomes in clinical practice.

Benefits of Participating:
• Review the latest clinical trial evidence in context using clinical cases to optimize decision making in CLL
• Hear contrasting views on treatment strategies and discover areas for further research in CLL
• Learn the thought process of experts behind the management of specific patient cases across CLL and use these perspectives to confirm and update your practice
• Apply the latest data to select treatments with the goal to minimize adverse events and reduce toxicity in patients with CLL

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Explain evidence-based therapeutic sequencing considerations and combination strategies for the treatment of CLL in the context of emerging strategies under clinical trial evaluation
• Distinguish among new small molecules under investigation for patients with CLL based upon mechanism of action, as well as recent safety and efficacy data
• Apply biomarker testing results to stratify risk among patients with CLL in frontline and relapsed/refractory treatment settings
• Use methods to optimize therapeutic efficacy and safety among patients with CLL in the context of emerging compounds and combination strategies